drugset / Trial / NCT04584736

To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

NCT04584736

Phase 3 Completed 283 enrolled JW Pharmaceutical
RandomizedFactorialQuadruple-blindTreatment

Summary

To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.

Timeline

Start
2019-06-11
Primary completion
2020-07-16
Completion
2020-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Pitavastatin Small molecule 2 mg
Subject Pitavastatin Small molecule 4 mg

Indications